معرفی
Professor Steve Griffin is a faculty member at the University of Leeds, serving as Professor of Cancer Virology within the Leeds Institute of Molecular Medicine, School of Medicine, Faculty of Medicine and Health. His research is centered on human virology with dual emphasis on emerging viruses with pandemic potential and the role of viruses in cancer development and therapy.
His research interests include:
- Development of antiviral therapies targeting viroporins in viruses such as HCV, SARS-CoV2, Zika, and influenza A.
- Understanding how HCV and human cytomegalovirus (hCMV) manipulate tissue progenitor cells to initiate liver and brain cancers.
- Investigating virus-mediated immunotherapy for liver cancers using oncolytic viruses combined with tyrosine kinase inhibitors.
The laboratory employs structural biology, molecular dynamics, and medicinal chemistry to identify druggable targets and develop specific antiviral compounds. These inhibitors also serve as tools to study viroporin function in viral life cycles. In cancer research, the group explores persistent oncogenic risk post-HCV cure and the controversial link between hCMV and glioblastoma. In immunotherapy, they aim to enhance immune responses against liver tumors by combining modified oncolytic viruses with tumor conditioning strategies.
No recent articles are listed in the provided text, but the research demonstrates a strong interdisciplinary trend spanning virology, oncology, immunology, and drug development.
No scientific awards are mentioned in the provided content.
Professor Griffin advises students and leads research projects in viral oncology and antiviral development, though specific names of advisees are not listed. His lab is actively involved in grant-funded research related to emerging viruses, cancer virology, and immunotherapeutic strategies. The work likely involves collaboration across virology, oncology, and pharmacology disciplines.
The research is conducted at the Wellcome Trust Brenner Building, Room 5.12, University of Leeds, where Professor Griffin leads a dynamic laboratory focused on translational virology and cancer therapeutics.
